Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

Blood thinner recalled due to potential cancer risk

The recall, announced by the FDA, includes multiple lots of dabigatran etexilate capsules.

Steven Nissen, MD, chief academic officer of the Heart, Vascular and Thoracic Institute, Cleveland Clinic, explains the details from the late-breaking CLEAR Outcomes trial presented at the 2023 American College of Cardiology (ACC) meeting found bempedoic acid can be used in statin-intolerant patients to reduce low-density lipoprotein (LDL) cholesterol levels. #ACC #ACC23 Nexletol

CLEAR Outcomes trial shows statin-intolerant patients benefit from bempedoic acid

Steven Nissen, MD, spoke with Cardiovascular Business at ACC.23 about the late-breaking CLEAR Outcomes trial.

Links to all the American College of Cardiology late-breaking studies for ACC.23

Here are links to more information on every late-breaking presentation at ACC.23.

ACC 2023 program chair Douglas Drachman, MD, explains the top takeaways from the American College of Cardiology meeting. #ACC #ACC23

Key takeaways from the ACC 2023 annual meeting

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Valentin Fuster, MD, PhD, director of Mount Sinai Heart and general director of the Spanish National Center for Cardiovascular Research

High dosage of blood thinners lowers 30-day morbidity for hospitalized COVID-19 patients

For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose. 

Large study finds high rates of nonadherence to statin recommendations; women especially averse

Many patients who would clearly benefit by lowered LDL cholesterol levels are choosing to forgo first-time recommendations for statin regimens, according to a population-level study. 

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

Thumbnail

Vericiguat consistently linked to positive outcomes, limited side effects among heart failure patients

Reviewing data from several studies, researchers wrote that vericiguat (Verquvo) could potentially "become a breakthrough in the treatment of heart failure." 

Displaying 233 - 240 of 373
Design by Adaptive Theme